Deborah Reed, MD
Neurology · Medina, OHNPI 1891808135
Payments from drug & device makers
Across 1,263 payments — averaging $374.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$109K
- Teva Pharmaceuticals USA, Inc.$99K
- AbbVie$64K
- Amgen$64K
- Lundbeck LLC$28K
- Biohaven Pharmaceuticals, Inc.$21K
- plus $86K from 26 others
What the payments were for
- Consulting fees$56,86714%
- Speaking & faculty fees$299,12676%
- Grants$880%
- Travel & lodging$15,1774%
- Food & beverage$22,7616%
- Education$2040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 240 | $109,499 |
| Teva Pharmaceuticals USA, Inc. | 297 | $98,936 |
| AbbVie(2 entities) | 219 | $64,446 |
| Amgen | 94 | $64,250 |
| Lundbeck LLC | 73 | $28,138 |
| Biohaven Pharmaceuticals, Inc. | 45 | $21,335 |
| Biohaven Pharmaceutical Holding Company Ltd. | 51 | $19,557 |
| H. Lundbeck A S | 3 | $17,700 |
| Eli Lilly | 3 | $15,417 |
| Impel Pharmaceuticals Inc. | 9 | $12,768 |
| Pfizer | 47 | $3,861 |
| Novartis | 27 | $3,219 |
| Axsome Therapeutics, Inc. | 6 | $2,889 |
| Biodelivery Sciences International, Inc. | 1 | $2,500 |
| Tonix Medicines, Inc. | 8 | $2,399 |
| Bausch Health US, LLC | 7 | $2,069 |
| Scilex Pharmaceuticals Inc. | 4 | $2,052 |
| Supernus Pharmaceuticals, Inc. | 60 | $558 |
| Upsher-smith Laboratories LLC | 17 | $339 |
| Amneal Pharmaceuticals LLC | 15 | $236 |
| Impel Pharmaceuticals LLC | 7 | $122 |
| Arbor Pharmaceuticals, Inc. | 4 | $103 |
| Currax Pharmaceuticals LLC | 6 | $82 |
| Assertio Therapeutics, Inc. | 4 | $60 |
| Almatica Pharma LLC | 4 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| Zyla Life Sciences, Inc. | 2 | $34 |
| Merz North America, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 2 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$65,918
- AJOVY$51,063
- UBRELVY$50,442
- NURTEC ODT$43,019
- EMGALITY$36,192
- VYEPTI$26,912
- QULIPTA$22,840
- REYVOW$20,200
- Trudhesa$12,685
- ELYXYB - CELECOXIB$4,500
- Symbravo$2,659
- ZEMBRACE SYMTOUCH$2,135
- TOSYMRA$2,135
- MIGRANAL$2,000
- BOTOX$102
- Austedo XR$100
How this compares
$472,775 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 161 | $245,991 |
| UbrelvyUbrogepant | 158 | $235,689 |
| Emgality SyringeGalcanezumab-Gnlm | 71 | $138,959 |
| Aimovig AutoinjectorErenumab-Aooe | 154 | $128,105 |
| Emgality PenGalcanezumab-Gnlm | 136 | $108,807 |
| TrudhesaDihydroergotamine Mesylate | 19 | $83,815 |
| QuliptaAtogepant | 46 | $48,667 |
| Trokendi XrTopiramate | 20 | $35,837 |
| ReyvowLasmiditan Succinate | 38 | $28,600 |
| OxycontinOxycodone Hcl | 31 | $24,296 |
| Ajovy SyringeFremanezumab-Vfrm | 23 | $23,956 |
| Sumatriptan Succinate | 247 | $17,206 |
| Dihydroergotamine Mesylate | 14 | $14,860 |
| Fentanyl | 24 | $6,095 |
| Almotriptan Malate | 24 | $5,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $64,446 | $284,356204 claims |
| PfizerNurtec Odt | $3,861 | $245,991161 claims |
| Impel Pharmaceuticals Inc.Trudhesa | $12,768 | $83,81519 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $558 | $35,83720 claims |
| Lilly USA, LLCReyvow | $109,499 | $28,60038 claims |
| Upsher-smith Laboratories LLCTopiramate | $339 | $96785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.
Other neurology in Medina
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
- Aram ZabetiCincinnati$5.3M
- Mark StillmanIndependence$4.6M
- Deren HuangNewark$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.